The combination of danoprevir and Roche's experimental drug RG7128 appeared safe and well-tolerated in hepatitis C patients compared with placebo during an early-stage study. Those who received the highest doses of both drugs twice a day demonstrated a significant reduction in viral load after 13 days.

Full Story:

Related Summaries